filovirus
ebola
viru
marburg
viru
caus
outbreak
highli
lethal
haemorrhag
fever
filoviru
mortal
rate
averag
greater
highest
record
mortal
rate
ebola
zair
viru
marburg
angola
viru
infect
haemorrhag
fever
virus
induc
sustain
high
fever
follow
aberr
coagul
vascular
permeabl
caus
bleed
bruis
rash
asymptomat
incub
period
last
day
week
symptom
typic
viral
infect
emerg
headach
nausea
fever
malais
preced
seriou
haemorrhag
symptom
fatal
case
death
result
multiorgan
failur
owe
shock
treatment
filoviru
infect
palli
consist
primarili
support
care
includ
hydrat
pain
manag
filoviru
outbreak
occur
equatori
africa
rang
ivori
coast
west
uganda
east
occasion
marburg
viru
kenya
far
south
angola
concentr
central
africa
particularli
democrat
republ
congo
republ
congo
uganda
outbreak
epidemiolog
investig
link
index
human
case
anim
contact
either
nonhuman
primat
antelop
travel
mine
presum
exposur
bat
recent
identifi
possibl
natur
reservoir
filovirus
recoveri
three
marburg
viru
isol
transmiss
human
gener
requir
close
contact
blood
bodi
fluid
care
ill
burial
practic
includ
bath
deceas
outbreak
control
facilit
patient
isol
use
protect
equip
avoid
contamin
needl
public
health
respons
direct
toward
surveil
diagnosi
commun
educ
effect
treatment
cure
therefor
vaccin
develop
crucial
import
strategi
minim
public
health
societ
econom
impact
natur
filoviru
outbreak
howev
vaccin
efficaci
test
ebola
viru
difficult
readili
identifi
highrisk
popul
target
placebocontrol
clinic
efficaci
trial
outbreak
unpredict
sporad
geograph
tempor
regulatori
approv
vaccin
pathway
vaccin
licenc
includ
assess
toxic
immun
respons
efficaci
preclin
anim
studi
clinic
safeti
studi
phase
ii
clinic
efficaci
studi
phase
iii
tabl
clinic
efficaci
studi
usual
evalu
incid
rate
vaccin
individu
compar
placebo
recipi
typic
perform
popul
known
risk
particular
condit
set
known
incid
defin
allow
studi
design
assess
feasibl
vaccin
licens
base
analysi
candid
vaccin
safeti
profil
efficaci
observ
phase
iii
clinic
trial
public
health
need
case
known
correl
human
protect
defin
particular
pathogen
earlier
phase
iii
trial
use
predict
efficaci
support
licens
subsequ
vaccin
formul
sporad
natur
incid
ebola
viru
infect
select
human
popul
predict
allow
adequ
statist
power
phase
iii
efficaci
trial
moreov
immun
correl
protect
diseas
human
remain
unknown
therefor
use
assess
candid
vaccin
efficaci
facilit
licens
drug
biolog
efficaci
evalu
set
natur
infect
us
food
drug
administr
fda
promulg
new
regul
altern
licens
pathway
pharmaceut
product
target
highli
lethal
pathogen
fda
anim
rule
allow
approv
base
anim
efficaci
data
conduct
good
laboratori
practic
control
human
safeti
immunogen
data
conduct
good
clinic
practic
control
support
correl
protect
defin
anim
model
describ
fda
code
feder
regul
cfr
see
inform
anim
rule
intend
use
pathway
regulatori
review
way
licenc
anim
rule
vaccin
licens
applic
anim
rule
vaccin
ebola
viru
reason
probabl
way
develop
filoviru
vaccin
human
use
although
addit
complex
perform
good
laboratori
practic
experi
biosafeti
level
contain
challeng
approach
requir
understand
pathophysiolog
immun
protect
anim
speci
use
predict
human
efficaci
end
point
anim
efficaci
studi
must
correl
desir
effect
human
typic
surviv
benefit
attenu
sever
diseas
allow
determin
effect
doserespons
relationship
anim
human
fda
regulatori
review
approv
requir
data
substanti
vaccin
consider
reason
like
provid
benefit
human
case
therapeut
drug
anim
model
data
present
substanti
predict
therapeut
benefit
must
demonstr
effect
biochem
level
elucid
mechan
pathogen
toxic
exampl
implement
anim
rule
licens
pyridostigmin
bromid
pretreat
soman
nerv
ga
exposur
base
data
rhesu
macaqu
soman
pathophysiolog
well
character
see
inform
link
drug
inform
centr
drug
evalu
research
rhesu
macaqu
soman
irrevers
block
acetylcholinesteras
enzym
necessari
proper
neurotransmiss
data
support
licens
pyridostigmin
bromid
provid
evid
competit
revers
blocker
soman
bind
target
enzym
unlik
pharmacolog
therapeut
vaccin
design
block
molecular
target
instead
interrupt
pathogen
replic
cycl
prevent
infect
clear
virusinfect
cell
natur
host
defenc
mechan
constitut
protect
immun
licens
anim
rule
requir
data
show
marker
correl
protect
vaccineinduc
immun
predict
surviv
expos
host
identif
immun
correl
anim
requir
fda
approv
human
vaccin
date
vaccin
licens
anim
rule
paradigm
therefor
present
challeng
basic
translat
clinic
scientist
identifi
one
paramet
primari
immun
anim
predict
immunolog
protect
infect
test
human
clinic
trial
immun
correl
vaccin
protect
immun
correl
protect
vari
depend
mode
vaccin
rout
infect
natur
immunolog
measur
immun
assess
associ
diseas
outcom
specifi
mechanist
relationship
immun
marker
protect
immunolog
correl
associ
efficaci
vari
strength
quantit
predict
relationship
specif
immun
respons
diseas
purpos
review
use
definit
correl
provid
scholarli
review
specif
immun
respons
vaccin
close
associ
protect
infect
diseas
defin
endpoint
given
multifactori
natur
immunolog
protect
reliabl
correl
immun
also
determin
protect
reflect
underli
immun
mechan
respons
resist
infect
howev
correl
may
associ
protect
without
causal
relat
viru
clearanc
strength
correl
requir
support
licens
ebola
vaccin
specifi
anim
rule
balanc
pathogen
lethal
risk
infect
complex
immun
respons
mediat
protect
urgenc
public
health
need
ebola
viru
outbreak
unpredict
surviv
low
possibl
defin
human
correl
immun
natur
infect
retrospect
studi
rare
subject
clear
ebola
viru
infect
identifi
qualit
associ
immun
end
point
studi
identifi
predict
marker
surrog
protect
immun
purpos
ebola
vaccin
develop
immun
correl
surviv
establish
pathophysiolog
anim
model
close
resembl
human
diseas
select
immunolog
end
point
correl
assess
inform
knowledg
underli
mechan
protect
subject
remain
investig
ebola
viru
potenti
immun
effector
involv
viru
clearanc
may
depend
one
arm
immun
system
exampl
cellular
humor
immun
altern
may
depend
variou
compon
innat
adapt
immun
respons
determin
immun
correl
protect
must
therefor
evalu
rang
phenotyp
function
marker
immun
fig
cell
phenotyp
assess
precis
singlecel
level
exploit
marker
lineag
home
profil
memori
phenotyp
respect
among
other
phenotyp
defin
function
profil
exampl
relat
helper
function
surfac
marker
associ
central
cell
memori
cell
effector
memori
cell
termin
effector
phenotyp
similarli
b
cell
immunolog
end
point
captur
use
phenotyp
marker
includ
express
immunoglobulin
ig
class
function
assay
measur
vitro
effector
characterist
direct
viru
neutral
antibodydepend
cellular
cytotox
correl
vaccin
efficaci
affect
variabl
structur
stabil
specif
immunogen
also
influenc
mode
antigen
deliveri
process
host
therefor
select
immun
end
point
focus
initi
mediat
relev
vaccin
platform
exampl
protein
formul
often
process
endocyt
pathway
stimul
helper
cell
respons
promot
antibodi
product
contrast
genebas
vaccin
allow
synthesi
foreign
protein
within
cell
lead
process
antigen
proteasom
process
effect
elicit
cell
respons
also
elicit
antibodi
respons
genebas
vaccin
potenti
gener
broad
respons
abil
target
antigenpres
cell
apc
directli
properti
certain
viral
vector
qualiti
rang
vaccineinduc
immun
respons
therefor
influenc
specif
viral
vector
differ
apc
target
must
determin
empir
anim
model
vaccin
protect
immun
reagent
assay
avail
anim
model
ebola
viru
infect
protect
immun
immun
correl
ebola
viru
infect
best
defin
mice
owe
avail
inbr
strain
allow
quantit
vaccineinduc
humor
cellular
respons
guinea
pig
infecti
challeng
model
also
allow
us
defin
immun
correl
rodent
model
share
close
relat
coagul
defect
observ
xu
use
plasmid
dna
vector
encod
sequenc
ebola
viru
envelop
glycoprotein
gp
express
surfac
virion
virusinfect
cell
np
viral
nucleocapsid
protein
form
organ
lattic
synthes
intramuscular
vaccin
gp
vector
gener
potent
cytolyt
respons
week
first
immun
mice
gp
np
vector
induc
high
titr
antigenspecif
igg
antibodi
present
infecti
challeng
correl
surviv
guinea
pig
although
antibodi
level
provid
quantit
marker
immun
protect
passiv
transfer
hyperimmun
sera
anim
protect
naiv
recipi
similarli
role
ebola
viru
igg
correl
vaccin
protect
observ
mous
guinea
pig
immun
venezuelan
equin
enceph
gp
np
result
suggest
igg
complet
block
infect
requir
cofactor
present
serum
lack
appropri
effector
function
depend
affin
epitop
support
last
possibl
monoclon
antibodi
polyclon
ig
survivor
activ
infect
either
human
mice
show
success
protect
naiv
mice
diseas
confirm
ebola
virusdirect
antibodi
qualiti
variabl
influenc
way
gener
evid
rodent
model
ebola
viru
infect
suggest
vaccineinduc
igg
ebola
viru
gp
quantit
immun
end
point
reflect
magnitud
underli
combin
b
cell
vaccin
respons
like
cellular
respons
present
immun
current
avail
method
assess
end
point
lack
sensit
specif
reliabl
detect
inde
necessari
role
cell
function
unambigu
genet
knockout
adopt
transfer
studi
mice
compon
specif
target
delet
enhanc
likewis
natur
killer
cell
also
seem
function
complement
vaccineinduc
ebola
viru
antibodi
viru
clearanc
immun
correl
vaccin
protect
murin
model
ebola
viru
infect
reveal
pathway
mechan
immun
protect
unparallel
anim
model
howev
vaccin
approv
human
use
requir
use
speci
reliabl
reflect
human
diseas
nonhuman
primat
number
aspect
ebola
interact
differ
murin
human
infect
exampl
infect
mice
viru
isol
infect
human
must
adapt
serial
passag
regard
ebola
viru
infect
nonhuman
primat
close
mimic
diseas
pathogenesi
observ
human
therefor
immun
correl
vaccin
protect
must
defin
nonhuman
primat
despit
rel
pauciti
reagent
avail
discern
manipul
primat
mediat
immun
protect
discord
result
vaccin
efficaci
studi
mice
nonhuman
primat
observ
ebola
vaccin
import
elisa
enzymelink
immunosorb
assay
igg
immunolog
end
point
establish
dna
vaccin
mice
guid
investig
augment
genet
vaccin
strategi
viral
vector
capabl
elicit
highermagnitud
antibodi
respons
primat
possibl
plasmid
dna
alon
altern
vector
combin
screen
mice
identifi
regimen
yield
highest
elisa
igg
titr
ebola
viru
gp
tabl
success
immun
protect
nonhuman
primat
accomplish
use
heterolog
vaccin
dna
replicationdefect
recombin
adenoviru
rad
vector
encod
ebola
viru
gp
platform
show
highest
potenc
elicit
antigenspecif
antibodi
first
studi
use
vaccin
nonhuman
primat
effici
induc
hightitr
antibodi
cell
infecti
challeng
subsequ
assess
singleshot
rad
ebola
vaccin
omit
dna
prime
step
confirm
presenc
antigenspecif
elisa
igg
survivor
demonstr
reproduc
antibodi
respons
correl
protect
furthermor
ebola
vaccin
develop
macaqu
base
vesicular
stomat
parainfluenza
viruslik
particl
vlp
sinc
report
protect
immun
correl
presenc
virusspecif
antibodi
vaccin
survivor
infecti
challeng
efficaci
addit
vaccin
nonhuman
primat
clearli
establish
protect
immun
ebola
viru
infect
achiev
offer
opportun
detect
immun
correl
whether
immun
correl
protect
appli
across
vaccin
platform
remain
unknown
may
depend
whether
differ
vaccin
vector
elicit
relat
pathway
immun
confer
protect
challeng
noteworthi
vaccin
shown
effect
protect
nonhuman
primat
induc
antibodi
respons
tabl
efficaci
nonhuman
primat
vaccin
consist
associ
presenc
elisa
igg
infecti
challeng
pathophysiolog
clinic
symptom
nonhuman
primat
ebola
viru
infect
accur
recapitul
human
ebola
viru
observ
provid
import
lead
develop
ebola
vaccin
human
use
anim
model
therefor
satisfi
requir
vaccin
licens
use
anim
rule
howev
state
begin
review
vaccin
regulatori
review
facilit
quantit
measur
immun
predict
protect
infect
rigor
test
strength
elisa
igg
correl
immun
protect
predict
valu
igg
titr
evalu
use
sera
nonhuman
primat
subject
immun
ebola
vaccin
encod
variou
combin
gp
np
well
differ
mutat
version
gp
nearli
complet
surviv
predict
subject
gener
particular
prechalleng
titr
elisa
igg
gp
fig
licens
vaccin
demonstr
protect
efficaci
fda
approv
identif
precis
ebola
viru
igg
threshold
titr
depend
level
vaccin
efficaci
specifi
surviv
rate
fig
establish
lower
threshold
immun
correl
protect
fig
requir
vaccin
efficaci
probabl
balanc
risk
mortal
differ
exposur
situat
elisa
igg
serv
use
exampl
immun
correl
protect
cynomolgu
macaqu
immun
vaccin
howev
may
definit
correl
bridg
gap
anim
human
immun
respons
vaccin
licens
question
remain
whether
addit
correl
increas
valu
elisa
igg
predict
protect
immun
ebola
viru
subject
mount
quantit
similar
antibodi
titr
exhibit
differ
surviv
outcom
offer
opportun
explor
function
attribut
antibodi
may
enhanc
distinct
survivor
fatal
base
antibodi
qualiti
although
direct
vitro
viru
neutral
assay
predict
protect
nonhuman
primat
effector
function
occasion
report
sampl
ebola
vaccineimmun
recent
antibodydepend
cellular
cytotox
detect
vaccin
neither
effector
function
quantit
correl
protect
immun
howev
data
impli
elisa
igg
titr
may
inde
reflect
activ
underli
immunolog
compon
addit
role
cell
antibodi
effector
function
mechan
immun
system
confer
protect
also
like
involv
cell
although
elisa
igg
quantit
reliabl
correl
vaccin
efficaci
immun
protect
transfer
immun
serum
naiv
rodent
passiv
transfer
fail
protect
nonhuman
primat
suggest
mechan
immun
protect
ebola
viru
infect
primat
complex
nj
unpublish
observ
furthermor
mous
adopt
transfer
knockout
studi
implic
b
cell
mediat
protect
immun
suggest
mechan
vaccinegener
ebola
viru
immun
probabl
multifacet
even
mice
mechan
protect
primat
might
similarli
complex
inde
preliminari
immunodeplet
studi
cell
subset
macaqu
suggest
cellular
immun
requir
viru
clearanc
nj
unpublish
observ
mechanist
studi
necessarili
translat
identif
prechalleng
correl
immun
immun
correl
protect
probabl
relat
underli
mechan
viru
clearanc
exampl
cytotox
lymphocyt
ctl
requir
observ
correl
surviv
vaccineinduc
antibodi
titr
may
simpli
reflect
cell
activ
simultan
provid
b
cell
costimul
helper
function
need
ctl
activ
absenc
neutral
activ
associ
igg
correl
suggest
antibodi
contribut
directli
clearanc
virusinfect
cell
host
despit
mechanist
evid
cellular
immun
vaccineinduc
immun
protect
anim
model
ebola
viru
infect
cell
respons
either
low
near
assay
limit
detect
inconsist
observ
howev
strong
possibl
tradit
assay
lack
sensit
need
detect
relev
determin
cellmedi
immun
vaccineinduc
cellular
respons
tradit
assess
measur
level
antigeninduc
effector
function
prolifer
cytolyt
kill
cytokin
secret
specif
lymphocyt
lineag
ex
vivo
stimul
relev
antigen
method
requir
extend
vitro
cultur
somewhat
artifici
may
captur
comprehens
cell
potenti
especi
memori
popul
display
typic
effector
function
newer
moresensit
method
analysi
cellular
immun
offer
promis
moredetail
assess
cell
phenotyp
function
fig
furthermor
advanc
approach
evalu
complex
inform
polychromat
flow
cytometri
cell
assay
open
new
possibl
use
elucid
addit
immun
addit
relev
immunolog
end
point
reveal
analys
may
prove
benefici
complement
elisa
igg
predict
vaccin
efficaci
achiev
determin
immun
filovirus
may
need
measur
combin
specif
immunolog
function
includ
antibodi
cellular
respons
filovirus
virus
herp
simplex
viru
hepat
c
viru
may
requir
discoveri
new
approach
measur
cellular
immun
complex
protect
immun
increas
less
like
measur
translat
accur
anim
model
human
therefor
immedi
goal
filoviru
vaccin
develop
defin
reliabl
correl
use
support
licens
vaccin
base
anim
rule
ultim
strength
antibodi
cell
correl
confirm
human
clinic
trial
use
final
candid
vaccin
compar
analysi
nonhuman
primat
human
immun
respons
immun
correl
ebola
vaccin
immun
nonhuman
primat
provid
basi
evalu
vaccin
protect
lethal
challeng
immunogen
human
although
confirm
could
theoret
deriv
survivor
natur
ebola
viru
infect
subject
rare
time
recoveri
variabl
first
outbreak
ebola
viru
total
survivor
cohort
constitut
identifi
case
therefor
analys
human
immun
respons
perform
retrospect
variabl
time
small
number
subject
noteworthi
presenc
ebola
virusspecif
elisa
igg
associ
surviv
natur
addit
immunolog
marker
segreg
human
surviv
natur
infect
includ
specif
human
leukocyt
antigen
class
b
cell
activ
assess
cytokin
correl
paramet
observ
therefor
fall
short
defin
predict
indic
protect
immun
addit
possibl
discern
whether
survey
immunolog
end
point
reflect
mediat
protect
simpli
memori
respons
gener
exposur
viru
ultim
licens
vaccin
human
use
requir
bridg
immun
correl
pivot
anim
efficaci
studi
placebocontrol
clinic
trial
human
volunt
fig
end
phase
random
human
clinic
trial
complet
ebola
dna
vaccin
first
ebola
vaccin
clinic
trial
show
vaccin
individu
immun
three
dose
gener
posit
antibodi
titr
measur
elisa
gp
np
antibodi
present
individu
regardless
vaccin
dose
rang
mg
rang
antibodi
titr
similar
observ
nonhuman
primat
vaccin
similar
indic
monkey
model
valid
predictor
human
immun
respons
ebola
viru
antigen
ebola
vaccin
demonstr
antigenspecif
protect
immun
infect
monkey
efficaci
correl
quantit
gpspecif
elisa
igg
titr
antigenspecif
cell
respons
also
elicit
vaccin
particularli
dna
boost
immun
probabl
contribut
viru
clearanc
immun
protect
although
mechan
protect
primat
fulli
defin
pathophysiolog
rodent
infect
differ
human
nonhuman
primat
immun
mechan
correl
protect
reliabl
determin
nonhuman
primat
infecti
challeng
studi
develop
moresensit
specif
cell
immun
assay
nonhuman
primat
could
aid
effort
defin
immunolog
end
point
relev
vaccin
licens
gene
knockout
target
specif
immun
function
nonhuman
primat
yet
perfect
immunodeplet
reagent
specif
discret
immun
cell
subset
help
elucid
immun
protect
mechan
ebola
viru
done
pathogen
smallpox
ref
studi
strengthen
confid
present
futur
immun
correl
predict
ebola
vaccin
efficaci
human
applic
anim
rule
diseas
vaccin
licens
use
anim
rule
applic
number
pathogen
tradit
clinic
efficaci
trial
possibl
diseas
includ
caus
highli
pathogen
agent
preclud
human
test
direct
challeng
would
requir
expos
healthi
human
volunt
lethal
substanc
popul
risk
natur
infect
identifi
efficaci
trial
center
diseas
control
propos
list
categori
aprior
pathogen
would
includ
viral
agent
ebola
viru
marburg
viru
smallpox
virus
well
bacteri
agent
caus
plagu
botul
anthrax
although
agent
pose
immedi
public
health
concern
unit
state
anim
rule
intend
provid
pathway
licens
vaccin
use
worldwid
highli
transmiss
agent
could
use
bioweapon
way
vaccin
therapeut
intervent
could
licens
advanc
threat
stockpil
use
emerg
addit
rule
would
also
prove
use
natur
infect
episod
unpredict
natur
west
nile
viru
avian
influenza
sar
sever
acut
respiratori
syndrom
diseas
threaten
public
health
episod
yet
becom
establish
suffici
larg
popul
allow
clinic
efficaci
studi
conclud
remark
date
vaccin
receiv
regulatori
approv
licens
use
fda
anim
rule
provid
framework
understand
regulatori
pathway
studi
vaccineinduc
protect
immun
respons
anim
might
provid
support
licens
pathway
diminish
level
regulatori
review
requir
vaccin
approv
extens
human
test
still
requir
demonstr
safeti
immunogen
furthermor
data
support
licens
may
actual
exceed
requir
tradit
approv
process
immun
correl
vaccin
protect
must
also
reveal
requir
current
use
licens
us
vaccin
predict
relationship
anim
human
protect
efficaci
unknown
therefor
immun
correl
use
bridg
gap
anim
efficaci
studi
human
immunogen
trial
yet
determin
level
efficaci
anim
requir
vaccin
approv
vaccin
current
administ
us
popul
provid
efficaci
human
trial
low
higher
potenc
may
requir
vaccin
approv
use
anim
rule
expect
would
highli
effect
use
emerg
even
level
efficaci
provid
substanti
benefit
pathogen
high
mortal
therefor
may
accept
level
countermeasur
emerg
natur
infect
deliber
biodef
threat
